Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VRTX

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

Barchart

Vertex Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

While Vertex Pharmaceuticals has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Vertex Pharmaceuticals’ Q1 2025 Earnings: What to Expect

Vertex Pharmaceuticals is set to unveil its Q1 results in the upcoming month, and analysts expect a double-digit drop in earnings.

Barchart

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

3 Pharmaceutical Stocks With Blockbuster Drug Potential

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors might consider adding three well-positioned biotech stocks such as Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN), and Gilead Sciences (GILD), for potential gains. Learn more….

StockNews.com

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Genomic Stocks at the Forefront of Precision Medicine

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector continues to evolve, investing in genomic stocks like Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) could be beneficial. Read on….

StockNews.com

3 Biotech Stocks Revolutionizing Healthcare

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth. Thus, investing in fundamentally stable stocks, Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD), could be a wise way to capitalize on the industry’s growing momentum. Read more….

StockNews.com

Vertex Pharmaceuticals Earnings Preview: What to Expect

With Vertex Pharmaceuticals gearing up to release its fourth-quarter earnings next month, analysts predict a single-digit drop in profit.

Barchart

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

StockNews.com

3 Biotech Stocks With Promising Pipelines

The biotech sector’s AI-driven advancements, personalized medicine demand, and streamlined regulations fuel significant market growth. Hence, investors should consider robust biotech stocks such as Vertex Pharmaceuticals (VRTX), Amgen (AMGN), and Gilead Sciences (GILD). Read on.

StockNews.com

Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Despite Vertex Pharmaceuticals’ recent underperformance compared to the Dow Jones, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks to Watch as Gene Therapy Gains Momentum

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and improve treatment options. Given this favorable trend, it could be wise to watch strong pharma stocks such as Vertex Pharmaceuticals (VRTX), Wave Life Sciences (WVE), and Poseida Therapeutics (PSTX). Read more.

Barchart

What You Need to Know Ahead of Vertex Pharmaceuticals' Earnings Release

Vertex Pharmaceuticals will unveil its Q3 earnings next month, and analysts project a lower-single-digit bottom-line growth.

Barchart

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Barchart

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

StockNews.com

3 Biotech Stocks With Revolutionary Pipelines to Buy Today

The biotech industry is experiencing rapid growth owing to new drug innovations and advancements in healthcare. To capitalize on the industry's expansion, it could be wise to invest in solid biotech stocks, Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD), which have revolutionary pipelines. Read on….

Barchart

What to Expect From Vertex Pharmaceuticals’ Next Quarterly Earnings Report

Vertex Pharmaceuticals will unveil its Q2 earnings next month, and analysts project a single-digit bottom-line growth.

Barchart

Is Vertex Stock Outperforming the S&P 500?

Vertex has outperformed the S&P 500 over the past year, and analysts are moderately bullish on the stock.

StockNews.com

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the surging popularity of plant-based products. Hence, quality biotech stocks, Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Jazz Pharmaceuticals (JAZZ) could be ideal investments for solid returns. Read more….

Investors Business Daily

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

StockNews.com

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

1 2 3 4 5

People

Kritika SarmahHer

727 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.